Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Melphalan for Retinoblastoma CNS Metastasis
NCT04903678Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- May 2021
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of melphalan in retinoblastoma (Rb), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Progression-Free Survival at 1 year, Overall Survival at 5 years and 2 more. Started May 2021; status: recruiting.
02
Drugs
melphalan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT04903678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903678.